

SHL TELEMEDICINE ISSUES AND LISTS NEW SHARES ON SIX SWISS EXCHANGE: THE ADVISOR

Posted on 18 February 2021



Category: [Capital Markets](#)

Tags: [Daniel Dedeyan](#), [Ex-Featured](#), [Nico Bernhard](#), [SHL Telemedicine](#), [Thomas Müller](#), [Walder Wyss](#)



Walder Wyss [has acted as Swiss counsel](#) and listing agent to SHL Telemedicine, a leading Israeli provider and developer of advanced personal telemedicine solutions listed on SIX Swiss Exchange (SIX), with regard to its recent capital increases, listing and private placement of new shares. SHL has raised about CHF 35 million by issuing a total of 3,888,889 shares at CHF 9.00 and has granted options to purchase further 1,944,444 new shares. The first trading day of the last tranche of the capital increases is 18 February 2021.

In connection with the listing of the new shares, Walder Wyss has assisted SHL in the submission of a listing prospectus for approval by SIX Exchange Regulation in its capacity as a Swiss Prospectus Office under the new Swiss statutory prospectus regime.

Daniel Dedeyan (Counsel, Capital Markets, team leader - pictured), Thomas Müller (Partner, Finance/Regulatory) and Nico Bernhard (Associate, Corporate/M&A) advised SHL in relation to all Swiss law aspects.